High prevalence of subclass-specific binding and neutralizing antibodies against Clostridium difficile toxins in adult cystic fibrosis sera: possible mode of immunoprotection against symptomatic C. difficile infection by Monaghan, TM et al.
© 2017 Monaghan et al. This work is published by Dove Medical Press Limited, and licensed under a Creative Commons Attribution License. 
The full terms of the License are available at http://creativecommons.org/licenses/by/4.0/. The license permits unrestricted use, distribution, 
and reproduction in any medium, provided the original author and source are credited.
Clinical and Experimental Gastroenterology 2017:10 169–175
Clinical and Experimental Gastroenterology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
169
O R I G I N A L  R E S E A R C H
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/CEG.S133939
High prevalence of subclass-specific binding and 
neutralizing antibodies against Clostridium difficile 
toxins in adult cystic fibrosis sera: possible mode 
of immunoprotection against symptomatic  
C. difficile infection
Tanya M Monaghan1
Ola H Negm2,3
Brendon MacKenzie4
Mohamed R Hamed2,3
Clifford C Shone5
David P Humphreys4
K Ravi Acharya6
Mark H Wilcox7
1Nottingham Digestive Diseases 
Centre, NIHR Nottingham Digestive 
Diseases Biomedical Research Unit, 
School of Medicine, University of 
Nottingham, Nottingham, 2Breast 
Surgery Group, Division of Medical 
Sciences and Graduate Entry Medicine, 
School of Medicine, Queen’s Medical 
Centre, University of Nottingham, 
Nottingham, UK; 3Medical Microbiology 
and Immunology Department, Faculty 
of Medicine, Mansoura University, 
Mansoura, Egypt; 4Antibody Biology, 
UCB-New Medicines, UCB Celltech, 
Slough, UK; 5Toxins Group, National 
Infection Service, Public Health England, 
Salisbury, UK; 6Department of Biology 
and Biochemistry, University of Bath, 
Bath, UK; 7Leeds Institute of Biomedical 
and Clinical Sciences, University of 
Leeds, Leeds, UK
Objectives: Despite multiple risk factors and a high rate of colonization for Clostridium dif-
ficile, the occurrence of C. difficile infection in patients with cystic fibrosis is rare. The aim of 
this study was to compare the prevalence of binding C. difficile toxin-specific immunoglobulin 
(Ig)A, IgG and anti-toxin neutralizing antibodies in the sera of adults with cystic fibrosis, symp-
tomatic C. difficile infection (without cystic fibrosis) and healthy controls. 
Methods: Subclass-specific IgA and IgG responses to highly purified whole C. difficile  toxins 
A and B (toxinotype 0, strain VPI 10463, ribotype 087), toxin B from a C. difficile toxin-B-only 
expressing strain (CCUG 20309) and precursor form of B fragment of binary toxin, pCDTb, 
were determined by protein microarray. Neutralizing antibodies to C. difficile toxins A and B 
were evaluated using a Caco-2 cell-based neutralization assay.
Results: Serum IgA anti-toxin A and B levels and neutralizing antibodies against toxin A were 
significantly higher in adult cystic fibrosis patients (n=16) compared with healthy controls (n=17) 
and patients with symptomatic C. difficile infection (n=16); p≤0.05. The same pattern of response 
prevailed for IgG, except that there was no difference in anti-toxin A IgG levels between the 
groups. Compared with healthy controls (toxins A and B) and patients with C. difficile infection 
(toxin A), sera from cystic fibrosis patients exhibited significantly stronger protective anti-toxin 
neutralizing antibody responses.
Conclusion: A superior ability to generate robust humoral immunity to C. difficile toxins in the 
cystic fibrosis population is likely to confer protection against symptomatic C. difficile infection. 
This protection may be lost in the post-transplantation setting, where sera monitoring of anti-C. 
difficile toxin antibody titers may be of clinical value.
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Introduction
Clostridium difficile (recently reclassified as Clostridioides difficile)1 is the leading 
worldwide infectious cause of hospital-acquired and antibiotic-associated diarrhea. 
The spectrum of clinical disease varies from asymptomatic colonization to fulminant 
colitis and death.2 Current understanding indicates that C. difficile pathogenesis is 
multifactorial, dictated by pathogenic toxin production, gut microbial dysbiosis, and 
altered host immune and inflammatory responses.3
Despite heavy antimicrobial pressure and frequent hospitalization, patients with cystic 
fibrosis have been reported to have a high carriage of C. difficile, but they rarely do manifest 
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symptoms or develop C. difficile infection.4–10 Asymptomatic 
carriers may be protected from progression to symptomatic 
infection because they can mount a humoral immune response to 
clostridial toxins.11 The main aim of this study was to investigate 
the prevalence of serum immunoglobulin (Ig)A and IgG antibod-
ies to C. difficile toxins in an adult cystic fibrosis population and 
to determine if sera from patients with cystic fibrosis contain 
protective neutralizing antibodies against the toxins.
Methods
Study population
In this retrospective matched cohort study, all available 
banked sera were collected over a 3-year period beginning 
in 2010 from diarrhea-free adult subjects with cystic fibrosis, 
adult subjects with C. difficile infection and healthy adult 
controls admitted to the Nottingham University Hospitals 
NHS Trust and were used to investigate the ability of the 
microarray assay to detect the presence of IgA and IgG 
directed against C. difficile microbial toxins and control 
antigens. Exclusion criteria for the control group included 
coexisting illnesses, gastrointestinal symptoms, or treatment 
with antibiotics or probiotics within the previous 6 months. 
For the cystic fibrosis cohort, all stool and blood samples 
were collected within 24–48 h of commencing intravenous 
antibiotics. Asymptomatic carriers were defined as those 
without diarrhea but with a positive stool culture for C. 
difficile. All patients in the C. difficile–infected group had 
diarrhea (defined as a change in bowel habit with three or 
more unformed stools per day for at least 48 h) and a posi-
tive stool C. difficile (enzyme immunoassay) toxin test. The 
diagnosis of cystic fibrosis had previously been made based 
on a positive sweat test and/or demonstration of two known 
cystic fibrosis mutations and typical clinical features of the 
disease. Clinical and demographic information were col-
lected from medical records. All subjects provided written 
informed consent for this study under the approvals granted 
by the Nottingham Research Ethics Committee. 
Toxin production and purification   
C. difficile toxins A and B were purified essentially as described 
previously12 with some modifications. Starter cultures (5 mL) 
of the C. difficile strain were used to inoculate each of the 8×2 
L vessels containing dialysis sacs (60 mL volume) and these 
were grown under anaerobic conditions for 90–96 h at 37°C. 
The contents of the dialysis sacs were then pooled, centrifuged 
at 10,000× g for 30 min, diluted 1:2 (v/v) with 50 mM bis-Tris 
buffer (pH 6.5) and the pH adjusted to pH 6.5. The diluted 
culture supernatant was applied onto a Q Sepharose column 
(GE Healthcare Life Sciences, Marlborough, MA, USA) 
equilibrated in 50 mM bis-Tris (pH 6.5) buffer, and toxins A 
and B protein peaks were eluted by a NaCl gradient. Toxin A, 
which was eluted using 200-300 mM of NaCI, was purified 
further by Chelating Sepharose Fast Flow (GE Healthcare Life 
Sciences) chromatography as described previously.12 Toxin 
B, which eluted between 500 and 700 mM NaCl, was further 
purified by chromatography on Mono Q (column size: 8 mL; 
GE Healthcare Life Sciences),  equilibrated in 50 mM bis-Tris 
(pH 6.5) buffer and eluted with a linear NaCl gradient.
Precursor form of B fragment of binary toxin pCDTb was 
produced in Escherichia coli from a wholly synthetic recom-
binant gene construct; using an amino acid sequence based on 
the published sequence from 027 ribotype (http:www.uni-
prot.org/uniprot/A8DS70). Detailed methods for cloning, 
expression and purification of pCDT are detailed elsewhere.13
Antigen microarray
Total specific IgA and IgG binding antibodies against the 
toxins were determined using a previously validated C. dif-
ficile protein microarray assay.14 Prior to study commence-
ment, we optimized both the dilution of the serum samples 
and concentration of printed antigens. The purity of all 
antigens tested in the current study was also evaluated using 
a silver stain (data not shown). For microarray, stored sera 
were profiled for total and specific IgA and IgG antibodies 
to highly purified C. difficile whole toxins A (200 μg/mL) 
and B (100 μg/mL) (toxinotype 0, strain VPI 10463, ribotype 
087, obtained from the American Type Culture Collection, 
Manassas, VA, USA), toxin B from a C. difficile toxin-B 
only expressing strain (CCUG 20309; 90 μg/mL)15 and 
precursor form of B fragment of binary toxin, pCDTb (200 
μg/mL). The optimum serum dilution for evaluation of IgA 
and IgG was 1:100 and 1:500 diluted in an antibody dilu-
ent (Dako, Glostrup Municipality, Denmark), respectively. 
Positive controls incorporated on each plate included tetanus 
toxoid (National Institute for Biological Standards and Con-
trol, Herts, UK) and lysates from Candida albicans (Jena 
Bioscience, Jena, Germany) containing the cytoplasm and 
cell wall. Negative controls included spotted printed buffer 
(phosphate-buffered saline; trehalose Tween) and no serum 
(blank) on each array. Alongside the aforementioned antigens 
and controls of interest, a human immunoglobulin standard 
(matching the antibody isotype) consisting of a 10-point 
two fold serial dilutions from 50 mg/mL to 24.4 ng/mL was 
spotted onto aminosilane slides (Schott Technical Glass 
Solutions GmbH, Jena, Germany) in quadruplicates using a 
MicroGridII arrayer (Digilab, Inc., Marlborough, MA, USA) 
and a silicon contact pin (Parallel Synthesis Technologies, 
Santa Clara, CA, USA). Human immunoglobulin standard 
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was used to normalize all the antigens and arrays to a com-
mon fluorescence intensity scale. 
Slides were scanned at 635 nm and the resultant images 
were processed with Genepix Pro-6 Microarray Image Analy-
sis software (Molecular Devices Inc., Sunnyvale, CA, USA). 
Protein signals were determined after background subtraction 
through customized modules in the R statistical language to 
general mean signal levels. Specific isotype responses were 
interpolated against the internal isotype standard curve for 
each sample.
Toxin neutralization assay
A Caco-2 cell-based neutralization assay for anti-toxin A and 
anti-toxin B neutralizing antibodies was used to investigate 
cytopathic effect and cell death as previously published.16 
Briefly, Caco-2 cells (HTB-37; American Type Culture Col-
lection) were maintained in minimal essential medium plus 
20% fetal calf serum, 2 mM glutamine and nonessential 
amino acids at 37°C. Serum samples were diluted in the assay 
medium at three dilutions (1:10, 1:100 and 1:1000), then 
premixed with toxin A or toxin B (at a dose inducing 50% 
cytopathic effect) for 1 h at 37°C before 50 μL of this mixture 
was transferred to the cells and incubated for an additional 96 
h. Following aspiration of the medium, 50 μL methylene blue 
(0.5% [wt/vol] dissolved in 50% [vol/vol] ethanol) was added 
to the cell culture and incubated for 1 h at room temperature. 
The cells were then washed gently with tap water (to remove 
excess stain) and air dried. The cells were then lysed by adding 
100 μL 1% (vol/vol) N-lauryl-sarcosine and incubated in a 
shaker for 15 min at room temperature. The cell biomass was 
determined by measuring the absorbance of each well using a 
BioTek Synergy2 (BioTeK, Winooski, VT, USA) plate reader 
at 405 nm. Toxin activity and 50% lethal dose concentrations 
were defined empirically in preliminary experiments and for 
each individual batch/lot of toxin used.
Statistical analysis
All statistical analyses were performed on natural log-
transformed data using GraphPad Prism version 6 (GraphPad 
software, San Diego, CA, USA). The unpaired t-test was 
used to compare the means of two independent samples. For 
grouped multiple comparisons, the Kruskall–Wallis test and 
the Dunn’s post hoc test were applied; p≤0.05 was deemed 
statistically significant. Demographic data were presented as 
medians and ranges. 
Results
The clinical characteristics of the three subject cohorts 
are highlighted in Table 1. Of the 16 patients in the cystic 
fibrosis cohort, two and one were found to be carriers 
of toxigenic and non-toxigenic C. difficile, respectively. 
Compared with patients with C. difficile infection, a higher 
proportion of patients with cystic fibrosis had preexisting 
diabetes mellitus. However, inflammatory bowel disease was 
only seen in the C. difficile-infected cohort. Although both 
patient groups had equal exposure to immunosuppressant 
drugs (defined as corticosteroids, calcineurin inhibitors, 
mTOR inhibitors, thiopurines and biologics), only patients 
(n=2) in the cystic fibrosis cohort had previous solid organ 
transplants. Usage of antibiotics (within the preceding 6 
months), proton pump inhibitor/H2 blockers and ursodeoxy-
cholic acid was higher in the cystic fibrosis cohort compared 
with the C. difficile-infected group. In unpaired t-tests, there 
were no significant differences between patients with cystic 
Table 1 Clinical and demographic characteristics
Subject characteristics Healthy controls (n=17) Cystic fibrosis patients 
(n=16)
Patients with C. difficile-associated 
diarrhea (n=16)
Age (years) 32 (22–89) 28 (19–49) 37 (19–49)
Male/female 8/9 8/8 3/13
Diabetes mellitus 0 11 3
Liver disease 0 3 2
Inflammatory bowel disease 0 0 4
PEG/NG feeding 0 3 1
Previous solid organ transplant 0 2 0
Immunosuppressants 0 5 5
Antibiotic usage (preceding 6 months) 0 16 10
PPI/H2 blocker usage 0 12 4
Ursodeoxycholic acid 0 3 0
Hospitalization (in preceding 6 months) 0 10 9
Previous CDI 0 1 2
Abbreviations: CDI, Clostridium difficile infection; NG, nasogastric tube; PEG, percutaneous endoscopic gastrostomy; PPI, proton pump inhibitor.
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fibrosis and C. difficile-infected cohorts in terms of mean 
(and standard deviation) white cell counts (8.7 [2.5] vs 9.4 
[4.6] × 109/L; p=0.59) or lymphocyte counts (1.8 [0.7] vs 
1.6 [0.6] × 109/L; p=0.35), respectively.
Serum samples from patients in the cystic fibrosis group 
exhibited significantly higher IgA antibody reactivities to 
C. difficile toxins A, B and toxin B (CCUG 20309) but not 
to pCDTb when compared with the healthy control and C. 
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Figure 1 Antibody class-specific responses to C. difficile toxins. 
Notes: Serum IgG and IgA antibody responses to C. difficile toxins A,  B (toxinotype 0, strain VPI 10463, ribotype 087; toxin A at concentration of 200 µg/mL, toxin B at 
concentration of 100 µg/mL), toxin B (C. difficile toxin B-producing strain CCUG 20309; toxin B at concentration of 90 µg/mL) and precursor form of B fragment of binary 
toxin, pCDTb (200 µg/mL), in patients with CF without diarrhea, CDI with diarrhea and HC. Serum dilution 1:500 for IgG and 1:100 for IgA. Differences between groups 
were calculated using the Kruskall–Wallis test followed by Dunn’s post hoc test for multiple responses. Box and whisker plots represent the median, range and quartiles. 
****p≤0.0001; ***p≤0.001; **p≤0.01; *p≤0.05. Standardized signals are normalized to immunoglobulin standard curve.
Abbreviations: C. difficile, Clostridium difficile; CDI, C. difficile infection; CF, cystic fibrosis; HC, healthy controls; Ig, immunoglobulin.
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difficile–infected patient groups (Figure 1). Serum IgG anti-
toxin B (both strains) and anti-pCDTb antibody levels were 
significantly higher in the cystic fibrosis cohort compared 
with healthy controls (Figure 1). Systemic IgG anti-toxin B 
antibody responses predominated and high titer sera did not 
correlate with high neutralizing potential (data not shown).
Sera in the cystic fibrosis group also contained signifi-
cantly higher levels of protective neutralizing anti-toxin A 
and anti-toxin B antibodies compared with the healthy control 
group (Figure 2). 
Discussion
We identified significantly higher levels of IgA anti-toxins 
A and B and neutralizing antibodies against toxin A in adult 
cystic fibrosis patients compared with healthy controls and 
patients with symptomatic C. difficile infection. This same 
antibody response prevailed for IgG, except that there was no 
difference in anti-toxin A IgG levels between the groups. Sera 
from cystic fibrosis patients also exhibited significantly stron-
ger protective anti-toxin neutralizing antibody responses com-
pared with healthy controls (toxins A and B) and patients with 
C. difficile infection (toxin A). Interestingly for pCDTb, IgG 
levels were also shown to be markedly higher for the cystic 
fibrosis group compared with the healthy control group. These 
observations support a previous report that suggests antibody 
responses to C. difficile toxins confer protection against 
clinical disease.11 Although limited by small sample size, 
our findings suggest that subclinical C. difficile infection is 
common among patients with cystic fibrosis. While both IgG 
and IgA anti-toxin antibodies may confer protection against 
symptomatic C. difficile infection in the cystic fibrosis popu-
lation, it is likely that the dominant functional  neutralizing 
antibody effect is exerted by IgG, which is associated with 
more mature high-affinity responses. When compared to 
healthy controls and patients with cystic fibrosis, our data 
are compatible with Islam et al’s study17 which showed lower 
levels of serum anti-toxin IgA in the group with C. difficile 
infection, which might reflect a poor/impaired gut mucosal 
immune response to toxin-mediated intestinal inflammation. 
Indeed, in the present study, the IgA binders appeared to be 
exclusive for toxin A in the cystic fibrosis group whereas anti-
toxin B associated with both IgG and IgA. While it has been 
proposed that C. difficile toxins may induce paradoxical killing 
of the fittest B cells and could explain why some individuals 
are prone to recurrent infections,18 we previously detected a 
higher proportion of circulating toxin-A-specific memory 
B cells in asymptomatic C. difficile-colonized patients with 
cystic fibrosis compared to non-cystic fibrosis patients with 
symptomatic C. difficile infection.19 These findings raise the 
possibility that patients with cystic fibrosis are able to mount 
more effective secondary B-cell immune responses that 
encode protective anti-toxin neutralizing antibodies compared 
with patients with C. difficile infection. Colonization with 
non-toxigenic C. difficile may also protect against colonization 
with toxigenic strains and may partially explain why patients 
with cystic fibrosis seldom develop symptomatic C. difficile 
infection.9,20 Moreover, it is conceivable that differences in 
colonic mucus or microbiome may protect patients with cystic 
fibrosis from C. difficile infection.
A limitation of this study is the small number of patients 
and a gender imbalance with a female preponderance in the 
group with C. difficile infection. The latter limitation may 
reflect the observation that population rates of C. difficile 
infection are commonly reported to be higher in women.21 
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Notes: Neutralizing antibody protection responses against C. difficile toxins A and B (toxinotype 0, strain VPI 10463, ribotype 087, used at LD50) in sera (1:100 dilution; toxin 
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Nevertheless, no gender-related differences in serum anti-
toxin immunoglobulin levels have been reported in patients 
with C. difficile infection in other studies.11,22 
Recent reports highlight that symptomatic C. difficile 
infection is a significant complication after solid organ and 
hematopoietic stem cell transplantation in cystic fibrosis and 
non-cystic fibrosis transplant recipients.23 In particular, cystic 
fibrosis patients who undergo lung transplantation are at a 
higher risk of developing C. difficile infection and seem to 
present with more atypical/severe disease.24 We speculate that 
a combination of host factors, including both B- and T-cell 
immunosuppression and/or an altered gut microbiome, is 
likely to contribute to the elevated risk in this population. 
These novel findings, if confirmed in larger studies, may 
support introduction of seromonitoring to identify transplant 
recipients displaying low levels of specific anti-toxin anti-
bodies who may be at risk of developing severe C. difficile 
infection. These individuals could be offered prophylactic 
passive or (when available) active immunotherapies.
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